TopiVert
TopiVert Ltd. is a clinical-stage biotechnology company based in London, United Kingdom, focused on developing narrow spectrum kinase inhibitors as locally-acting treatments for chronic inflammatory diseases affecting the gastrointestinal tract and the eyes. Founded in 2010, the company is advancing its lead program, TOP1288, which is undergoing a Phase IIa proof of concept study for ulcerative colitis. Additionally, TopiVert is preparing to initiate a Phase I/II study for its second program, TOP1630, aimed at addressing dry eye syndrome. The company's innovative approach enables the delivery of medications at pharmacologically relevant concentrations directly to the targeted areas, potentially leading to improved treatment outcomes for patients.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.